Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Polaryx Therapeutics Inc (PLYX)

Polaryx Therapeutics Inc (PLYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference ACN Newswire - Mon Aug 24, 10:59AM CDT

Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

CING : 5.68 (+2.34%)
SER : 2.63 (-8.36%)
GANX : 2.00 (-0.25%)
BIOA : 9.38 (-1.05%)
OSTX : 1.5500 (-2.52%)
VTVT : 33.89 (+1.91%)
MASS : 10.92 (+2.25%)
PYPD : 4.99 (-2.25%)
TKNO : 7.34 (-0.27%)
OVID : 2.82 (+0.71%)
MDCX : 0.2574 (-5.30%)
EQ : 2.20 (-4.76%)
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial GlobeNewswire - Thu May 28, 7:30AM CDT

PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying...

PLYX : 1.87 (-9.66%)
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards GlobeNewswire - Thu May 14, 8:15AM CDT

PARAMUS, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal...

PLYX : 1.87 (-9.66%)
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference GlobeNewswire - Thu Apr 23, 7:30AM CDT

PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal...

PLYX : 1.87 (-9.66%)
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial GlobeNewswire - Tue Apr 21, 7:30AM CDT

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today...

PLYX : 1.87 (-9.66%)
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care GlobeNewswire - Wed Apr 15, 8:15AM CDT

PARAMUS, NJ, April 15, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal...

PLYX : 1.87 (-9.66%)
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference GlobeNewswire - Wed Apr 1, 7:30AM CDT

PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal...

PLYX : 1.87 (-9.66%)
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) GlobeNewswire - Tue Mar 17, 7:30AM CDT

Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx...

PLYX : 1.87 (-9.66%)
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events GlobeNewswire - Thu Mar 12, 7:30AM CDT

PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal...

PLYX : 1.87 (-9.66%)
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders GlobeNewswire - Fri Feb 27, 7:30AM CST

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal...

PLYX : 1.87 (-9.66%)

Barchart Exclusives

Treasuries Have Reclaimed the Yield Crown From Dividend Stocks. Here’s How Income Investors Can Adapt. Barchart - Mon Aug 24, 6:30PM CDT
Treasuries have reclaimed the yield advantage, with fewer than 4% of S&P 500 stocks now yielding more than the 10-year Treasury (near 4.69%), compared with nearly 63% a decade ago. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.